Why Wall Street Sees Danaher (DHR) Benefiting From Improving Industry Conditions
Key takeaways
- On May 26, Citi resumed coverage of Danaher Corporation (NYSE:DHR) with a Buy rating and a $230 price target following a prior suspension of coverage.
- On May 14, RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating and a $200 price target.
- Founded in 1984, Danaher Corporation (NYSE:DHR) is headquartered in Washington, D.C.
Why Wall Street Sees Danaher (DHR) Benefiting From Improving Industry Conditions Sajjl Nooranne Mon, June 8, 2026 at 5:43 AM GMT+7 2 min read DHR C With 110 hedge fund holders as of Q1 2026, Danaher Corporation (NYSE:DHR) is among the Top 10 Stocks That Members of Congress Own.
On May 26, Citi resumed coverage of Danaher Corporation (NYSE:DHR) with a Buy rating and a $230 price target following a prior suspension of coverage. The firm pointed to Danaher’s reaffirmation of its fiscal 2026 core growth guidance during its first-quarter earnings report and expressed continued confidence in the outlook for the bioprocessing market. Citi noted that the company remains well-positioned to benefit from improving industry conditions and sustained demand across its life sciences portfolio.
On May 14, RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating and a $200 price target. The firm expects the company’s growth trajectory to strengthen as conditions in the bioprocessing market continue to recover. According to RBC, a sustained rebound in bioprocessing activity, the easing of company-specific headwinds, and improving end-market demand could enable Danaher to achieve its targeted 6% revenue growth rate by 2027, reinforcing confidence in its medium-term growth outlook.